18F-FDG PET/CT for Response Assessment in Lung Cancer

Marcus, Charles; Tajmir, Shahein; Rowe, Steven P.; Sheikhbahaei, Sara; Solnes, Lilja B.

doi:10.1053/j.semnuclmed.2022.04.001

Cited by 7 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…71% and 68% of CT, respectively [28]. This was related to accounting for metabolic changes on FDG-PET/ CT, enabling differentiation between viable tumor from non-viable scarring, fibrosis, or necrotic tissue.…”

Section: Role Of Fdg-pet/ct In Response Assessmentmentioning

confidence: 99%

“…PET/CT provides the opportunity to evaluate disease burden by using other parameters, such as metabolic tumor volume (MTV) and total lesion glycolysis (a composite parameter that integrates both intensity and volume and is generally calculated by multiplying the SUV mean by the MTV). Despite all these interesting concepts, and with many studies proving in some cases a better assessment compared to SUVs, for example, for a better predictor of progression-free survival [28], these parameters often lack standardization and appropriate and accurate easy-accessible software of evaluation. PET/CT is most useful when there is clinical suspicion or other evidence for disease recurrence or metastases He et al [11] 2014 1035 PET/CT, Diag.…”

Section: Semiquantitative and Quantitative Measurementsmentioning

confidence: 99%

“…In a meta-analysis of 13 studies of 414 patients, pathological assessment was used as the gold standard to compare the predictive outcome of FDG-PET/CT and CT in evaluating adjuvant therapy tumor response. FDG-PET/CT was found to be superior with a sensitivity of 83% and a specificity of 84%, compared to 71% and 68% of CT, respectively [28]. This was related to accounting for metabolic changes on FDG-PET/CT, enabling differentiation between viable tumor from non-viable scarring, fibrosis, or necrotic tissue.…”

Section: Role Of Fdg-pet/ct In Response Assessmentmentioning

confidence: 99%

See 2 more Smart Citations

PET/CT in treatment response assessment in lung cancer. When should it be recommended?

Bin Essa,

Kaplar,

Balaji

et al. 2023

Nuclear Medicine Communications

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Different treatment options are now possible both for surgical candidates and for those NSCLC patients deemed not suitable for surgery. Despite the treatments available, only a limited number of less advanced stages are potentially curable, with many patients suffering local recurrence or distant metastases. FDG-PET/CT is commonly used in many centers for post-treatment evaluation, follow-up, or surveillance; Nonetheless, there is no clear consensus regarding the indications in these cases. Based upon the results of a literature review and local expertise from a large lung cancer unit, we built clinical evidence-based recommendations for the use of FDG-PET/CT in response assessment. We found that in general this is not recommended earlier than 3 months from treatment; however, as described in detail the correct timing will also depend upon the type of treatment used. We also present a structured approach to assessing treatment changes when reporting FDG-PET/CT, using visual or quantitative approaches.

show abstract

Section: Role Of Fdg-pet/ct In Response Assessmentmentioning

confidence: 99%

Section: Semiquantitative and Quantitative Measurementsmentioning

confidence: 99%

Section: Role Of Fdg-pet/ct In Response Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

PET/CT in treatment response assessment in lung cancer. When should it be recommended?

Bin Essa,

Kaplar,

Balaji

et al. 2023

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…Conventional computed tomography (CT) relies mainly on the size of the lymph node to determine metastasis, with the diagnostic criterion being a short-axis diameter of > 1 cm, leading to high false-negative and false-positive rates [ 2 3 ]. Recently, positron emission tomography (PET)/CT has demonstrated great value in the diagnosis, staging, treatment, and prognosis of malignant lung tumors [ 4 5 6 ]. However, the examination cost is high, and false-positive uptake of 18 F-fluorodeoxyglucose ( 18 F-FDG) in the hilar and mediastinal lymph nodes is common [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

^99mTc-3PRGD₂ SPECT/CT Imaging for Diagnosing Lymph Node Metastasis of Primary Malignant Lung Tumors

Xiao,

Yu,

et al. 2023

Korean J Radiol

View full text Add to dashboard Cite

Objective To evaluate 99m technetium-three polyethylene glycol spacers-arginine-glycine-aspartic acid ( 99m Tc-3PRGD 2 ) single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging for diagnosing lymph node metastasis of primary malignant lung neoplasms. Materials and Methods We prospectively enrolled 26 patients with primary malignant lung tumors who underwent 99m Tc-3PRGD 2 SPECT/CT and 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)/CT imaging. Both imaging methods were analyzed in qualitative (visual dichotomous and 5-point grades for lymph nodes and lung tumors, respectively) and semi-quantitative (maximum tissue-to-background radioactive count) manners for the lymph nodes and lung tumors. The performance of the differentiation of lymph nodes with and without metastasis was determined at the per-lymph node station and per-patient levels using histopathological results as the reference standard. Results Total 42 stations had metastatic lymph nodes and 136 stations had benign lymph nodes. The differences between metastatic and benign lymph nodes in the visual qualitative and semiquantitative analyses of 99m Tc-3PRGD 2 SPECT/CT and 18 F-FDG PET/CT were statistically significant (all P < 0.001). The area under the receiver operating characteristic curve (AUC) in the semi-quantitative analysis of 99m Tc-3PRGD 2 SPECT/CT was 0.908 (95% confidence interval [CI], 0.851–0.966), and the sensitivity, specificity, positive predictive value, and negative predictive value were 0.86 (36/42), 0.88 (120/136), 0.69 (36/52), and 0.95 (120/126), respectively. Among the 26 patients (including two patients each with two lung tumors), 15 had pathologically confirmed lymph node metastasis. The difference between primary lung lesions in patients with and without lymph node metastasis was statistically significant only in the semi-quantitative analysis of 99m Tc-3PRGD 2 SPECT/CT ( P = 0.007), with an AUC of 0.807 (95% CI, 0.641–0.974). Conclusion 99m Tc-3PRGD 2 SPECT/CT imaging may notably perform in the direct diagnosis of lymph node metastasis of primary malignant lung tumors and indirectly predict the presence of lymph node metastasis through uptake in the primary lesions.

show abstract

Quantitative Nuclear Medicine in Cardiopulmonary Imaging

Jreige,

Prior

2024

Medical Radiology

View full text Add to dashboard Cite

18F-FDG PET/CT for Response Assessment in Lung Cancer

Cited by 7 publications

References 53 publications

PET/CT in treatment response assessment in lung cancer. When should it be recommended?

PET/CT in treatment response assessment in lung cancer. When should it be recommended?

^99mTc-3PRGD₂ SPECT/CT Imaging for Diagnosing Lymph Node Metastasis of Primary Malignant Lung Tumors

Quantitative Nuclear Medicine in Cardiopulmonary Imaging

Contact Info

Product

Resources

About

18F-FDG PET/CT for Response Assessment in Lung Cancer

Cited by 7 publications

References 53 publications

PET/CT in treatment response assessment in lung cancer. When should it be recommended?

PET/CT in treatment response assessment in lung cancer. When should it be recommended?

99mTc-3PRGD2 SPECT/CT Imaging for Diagnosing Lymph Node Metastasis of Primary Malignant Lung Tumors

Quantitative Nuclear Medicine in Cardiopulmonary Imaging

Contact Info

Product

Resources

About

^99mTc-3PRGD₂ SPECT/CT Imaging for Diagnosing Lymph Node Metastasis of Primary Malignant Lung Tumors